机译:改善程序安全后选择性眼科动脉输液化疗治疗眼视网膜母细胞瘤的方案安全性
Department of Radiology and Biomedical Imaging University of California San Francisco San;
Department of Radiology and Imaging Sciences University of Utah Salt Lake City UT USA;
Department of Ophthalmology University of California San Francisco San Francisco CA USA;
Department of Radiology and Biomedical Imaging University of California San Francisco San;
Department of Radiology and Biomedical Imaging University of California San Francisco San;
Department of Radiology and Biomedical Imaging University of California San Francisco San;
Department of Radiology and Biomedical Imaging University of California San Francisco San;
Department of Radiology and Biomedical Imaging University of California San Francisco San;
Department of Radiology and Biomedical Imaging University of California San Francisco San;
Interventional neurooncology; intra-arterial chemotherapy; retinoblastoma;
机译:改善程序安全后选择性眼科动脉输液化疗治疗眼视网膜母细胞瘤的方案安全性
机译:选择性眼内动脉美法仑治疗晚期视网膜母细胞瘤:新化疗方案的实施和结果
机译:摘要527号因子影响视网膜母细胞瘤(RB)对接受选择性眼球动脉输注化疗(SOAIC)的儿童治疗的反应
机译:钌106眼药水的剂量学分析视网膜母细胞瘤和眼黑素瘤的治疗
机译:化学疗法治疗晚期视网膜母细胞瘤的临床比较:动脉内和玻璃体内化疗与动脉内和静脉内化疗
机译:改变方案以选择性眼科动脉灌注化学疗法治疗眼视网膜母细胞瘤后提高了程序安全性
机译:单侧散发性D组视网膜母细胞瘤的一线动脉内或静脉内化疗:回顾性研究20年来的治疗,证明了较好的视觉效果,眼存活率和较短的成功率。